Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Vincerx Pharma Inc market cap is $83,748.00.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Vincerx Pharma Inc 52 week high is $0.0257 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Vincerx Pharma Inc 52 week low is $0.0002 as of November 22, 2026.
Vincerx Pharma Inc stock price today is $0.016.
Vincerx Pharma Inc stock price yesterday was $0.016.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Vincerx Pharma Inc 50-day moving average is $0.0161.